Get started
NOVO NORDISK A/SNN

NOVO NORDISK A/S

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

NOV chart


Full chart

Key facts today


A U.S. judge denied compounding pharmacies' request to produce copies of Novo Nordisk's Ozempic and Wegovy, enforcing an FDA deadline for larger facilities to exit by May 22, 2025.
In January 2025, Novo Nordisk released data from an early-stage drug trial of a dual-action obesity medication, showing that users lost an average of up to 22% of their body weight over 36 weeks.
DBS noted structural issues at Novo Nordisk, highlighting its heavy reliance on obesity care, which poses risks from supply constraints on GLP-1 products and may limit Wegovy's growth.
Analyze the impactAnalyze the impact

NOV upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪242.56 B‬ EUR
Dividend yield (indicated)
2.78%
Price to earnings Ratio (TTM)
17.94
Basic EPS (TTM)
3.03 EUR
Net income (FY)
‪13.50 B‬ EUR
Revenue (FY)
‪38.82 B‬ EUR
Shares float
‪3.16 B‬
Beta (1Y)
1.42

Employees


Employees (FY)
‪76.3 K‬
Change (1Y)
‪+12.93 K‬ +20.41%
Revenue / Employee (1Y)
‪508.83 K‬ EUR
Net income / Employee (1Y)
‪176.94 K‬ EUR

About NOVO NORDISK B A/S


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Lars Fruergaard Jørgensen
Website
novonordisk.com
Headquarters
Bagsværd
Founded
1931
ISIN
DK0062498333
FIGI
BBG000DYN996
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

NOV news



No news here

Looks like there's nothing to report right now

Reload

Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

NOV highest yielding bonds


N
XS282046075
NOVO NO.F.NL 24/34 MTN
Yield to maturity
3.22%
Maturity date
May 21, 2034
N
XS282045567
NOVO NO.F.NL 24/31 MTN
Yield to maturity
2.81%
Maturity date
Jan 21, 2031
XS244124704
NOVO NO.F.NL 22/30MTN
Yield to maturity
2.77%
Maturity date
Mar 31, 2030
N
XS282045460
NOVO NO.F.NL 24/29 MTN
Yield to maturity
2.49%
Maturity date
Jan 21, 2029
XS234803042
NOVO NO.F.NL 21/28
Yield to maturity
2.48%
Maturity date
Jun 4, 2028
N
XS282044994
NOVO NO.F.NL 24/26 MTN
Yield to maturity
2.46%
Maturity date
May 21, 2026
XS244933017
NOVO NO.F.NL 22/27MTN
Yield to maturity
2.42%
Maturity date
Sep 30, 2027

See all NOV bonds 

Sparks


Curated watchlists where NOV is featured.

See all sparks 

Frequently Asked Questions


The current price of NOV is 54.29 EUR — it has increased by 1.33% in the past 24 hours. Watch NOVO NORDISK A/S stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange NOVO NORDISK A/S stocks are traded under the ticker NOV.
NOV stock has fallen by −2.03% compared to the previous week, the month change is a −21.56% fall, over the last year NOVO NORDISK A/S has showed a −53.68% decrease.
We've gathered analysts' opinions on NOVO NORDISK A/S future price: according to them, NOV price has a max estimate of 153.63 EUR and a min estimate of 46.76 EUR. Watch NOV chart and read a more detailed NOVO NORDISK A/S stock forecast: see what analysts think of NOVO NORDISK A/S and suggest that you do with its stocks.
NOV reached its all-time high on Jun 26, 2024 with the price of 138.48 EUR, and its all-time low was 13.20 EUR and was reached on Jan 30, 2014. View more price dynamics on NOV chart.
See other stocks reaching their highest and lowest prices.
NOV stock is 3.93% volatile and has beta coefficient of 1.42. Track NOVO NORDISK A/S stock price on the chart and check out the list of the most volatile stocks — is NOVO NORDISK A/S there?
Today NOVO NORDISK A/S has the market capitalization of ‪243.23 B‬, it has increased by 0.27% over the last week.
Yes, you can track NOVO NORDISK A/S financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S is going to release the next earnings report on May 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NOV earnings for the last quarter are 0.85 EUR per share, whereas the estimation was 0.80 EUR resulting in a 6.08% surprise. The estimated earnings for the next quarter are 0.82 EUR per share. See more details about NOVO NORDISK A/S earnings.
NOVO NORDISK A/S revenue for the last quarter amounts to ‪11.46 B‬ EUR, despite the estimated figure of ‪10.71 B‬ EUR. In the next quarter, revenue is expected to reach ‪10.46 B‬ EUR.
NOV net income for the last quarter is ‪3.77 B‬ EUR, while the quarter before that showed ‪3.66 B‬ EUR of net income which accounts for 3.14% change. Track more NOVO NORDISK A/S financial stats to get the full picture.
NOVO NORDISK A/S dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 25, 2025, the company has ‪76.3 K‬ employees. See our rating of the largest employees — is NOVO NORDISK A/S on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S EBITDA is ‪19.99 B‬ EUR, and current EBITDA margin is 50.95%. See more stats in NOVO NORDISK A/S financial statements.
Like other stocks, NOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NOVO NORDISK A/S technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NOVO NORDISK A/S stock shows the sell signal. See more of NOVO NORDISK A/S technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.